No Data
Beijing Beilu Pharmaceutical (300016.SZ): Renewed the concerted action agreement.
On December 16, Glonghui reported that Beijing Beilu Pharmaceutical (300016.SZ) announced that the company has recently renewed the "Joint Action Agreement" with Ms. Zeng Chunhui, the second largest Shareholder of Haichang Pharmaceutical. This renewal of the "Joint Action Agreement" has not led to a change in the actual control of Haichang Pharmaceutical, and the controlling Shareholder of Haichang Pharmaceutical remains the company. The renewal of the "Joint Action Agreement" is beneficial for the company to maintain the stability of the actual control of its holding subsidiary Haichang Pharmaceutical, ensuring consistency in major decision-making matters at Haichang Pharmaceutical, and is favorable for the coherence and stability of the company's Global Strategy and Operations management, and will not have an impact on the daily operations management of the company and Haichang Pharmaceutical.
beijing beilu pharmaceutical (300016.SZ) obtained GMP certification from the Brazilian National Health Surveillance Agency.
Beijing Beilu Pharmaceutical (300016.SZ) announced that recently, the company has obtained approval from the Brazilian National Health Surveillance Agency ("ANVISA")...
Hokuriku Pharmaceutical: Third quarter report 2024
Beijing Beilu Pharmaceutical (300016.SZ): Gadoxetic Acid Glucosamine Injection passed the consistency evaluation.
On October 21st, Beijing Beilu Pharmaceutical (300016.SZ) announced that the company recently received the approval and issuance of specifications of gadolinium diethylenetriaminepentaacetic acid glucosamine injection: 10ml: 4.69g, 12ml: 5.63g, in the 'Supplementary Application Approval Notice for Pharmaceutical Products' (Notice Numbers: 2024B04775, 2024B04774). Gadolinium diethylenetriaminepentaacetic acid glucosamine injection (10ml: 4.69g, 12ml: 5.63g) has passed the evaluation of generic drug quality and efficacy consistency. Gadolinium diethylenetriaminepentaacetic acid glucosamine injection is a commonly used paramagnetic contrast agent in domestic clinical practice.
Beijing Beilu Pharmaceutical (300016.SZ): Haichang Pharmaceutical passed the pharmaceutical GMP compliance inspection.
Beijing Beilu Pharmaceutical (300016.SZ) announced that the company's holding subsidiary Zhejiang Haichang Pharmaceutical Co., Ltd. (referred to as "...
Beijing Beilu Pharmaceutical (300016.SZ): Currently has a production line for iodine contrast agents with an annual output of 1000 tons, totaling 7 varieties.
Beijing Beilu Pharmaceutical (300016.SZ) received specific inquiries on September 11, 2024 regarding the 'company's capacity utilization'. The company stated that the current capacity utilization of Beijing Beilu Pharmaceutical can meet the business development needs for the next two to three years. In order to meet the continuous growth demands of future business, the company is actively expanding its capacity. As an important subsidiary of the company, Haichang Pharmaceutical has added 50 tons of iodinated sea alcohol API production capacity in 2023 and increased the production line for 100 tons of iodinated mepivacaine API, which currently includes a total of 7 varieties of production lines for annual production of 1,000 tons of iodinated contrast agent projects.
No Data
